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Abstract
Background: Epidural fibrosis is regarded as a cause of failed back surgery syndrome (FBSS) when
excessive adhesional/fibrotic scar tissue causes compression, pain or discomfort by tethering of
nerve tissue to the surrounding muscle or bone. Fibrosis inhibitors could therefore increase the
success rate of spinal surgery and decrease the need for reoperations. In recent years, bio-
resorbable gels or films for the prevention of peridural fibrosis and post-operative adhesions have
been developed that look clinically promising. This included a 100% synthetic, sterile, absorbable
gel combinations of carboxymethylcellulose (CMC) and polyethylene oxide (PEO) used to coat the
dura to reduce scarring after discectomy which became available in Europe in 2002. However, given
the burden of the problem and unfavorable experience with other types of adhesion-reduction
agents, our unit decided to evaluate the safety of CMC/PEO in a large population of patients
undergoing spinal microdiscectomy for herniation.
Methods: To determine the safety and assess efficacy of carboxymethylcellulose/polyethylene
oxide (CMC/PEO) gel as an anti-adhesion gel, a consecutive series of 396 patients undergoing
lumbar discectomy performed by one surgeon had CMC/PEO gel administered at the end of
surgery. The patients were followed up in accordance with standard clinical practice and records
reviewed for side effects, such as skin reactions, general reactions or local fluid collections.
Reoperations for recurrent herniation included an evaluation of fibrosis reduction.
Results: No product related complications were observed. Five patients needed reoperations for
recurrent herniation. Significant but subjective reduction in fibrosis was observed in these patients.
Conclusion: The findings provide confidence that CMC/PEO gel is well tolerated as an agent to
achieve reduction of fibrosis in lumbar disc surgery. Further formal prospective study is
recommended in this area of unmet need.
Background
Although normal healing involves the migration of
fibroblasts to a wound site to form a matrix of scar tissue,
excessive scar tissue may cause impairment in function,
either by direct compression or by tethering of nervous tis-
sues to the surrounding muscle or bone. Such epidural
fibrosis is estimated as contributing to 60% of all cases of
recurring back pain symptoms in the heterogeneous con-
dition known as failed back surgery syndrome (FBSS)
which occurs after discectomy or laminectomy [1]. The
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direct costs of further diagnostic measures, treatments and
repeat surgery, as well as additional societal costs, empha-
size the importance of preventive measures during sur-
gery. While spinal surgeons have responded to this
challenge by improvements in surgical technique, the
problem remains and use of an interposition agent to
reduce scarring after discectomy is recognized in the
recent Cochrane review as likely to be an important strat-
egy [2].
Recently several types of bioresorbable gels applied
directly to the organs and acting as a chemical or physical
barrier to surgical adhesions have been approved by
licensing regulators. As devices, they are subject to differ-
ent approval criteria than drug products and since the type
of procedures which use these devices are often limited in
numbers, the initial safety and efficacy data can often be
based on small numbers of patient experiences.
The importance of close monitoring and the collection of
safety data when new devices first receive approval for
routine use should not be underestimated. Recently,
Adcon-L®, a promising agent licensed for use as an adhe-
sion-reduction device in laminectomy, was withdrawn
after approval due to serious adverse events [3-5] which
were not apparent in the early clinical trials [6-8].
In light of such events we decided to prospectively evalu-
ate the safety of a new adhesion-reduction device, car-
boxymethylcellulose (CMC) and polyethylene oxide
(PEO) gel, in a consecutive series of patients undergoing
spinal microdiscectomy for herniation. Such a study is in
accordance with the essential requirements of the Medical
Devices Directive [9] and it is good surgical practice to
closely monitor use of any new technique, device or other
treatment as it is introduced into routine surgery.
Methods
CMC and PEO have separately demonstrated anti-adhe-
sion properties [10-12] and have a good safety record in
widespread clinical use. The combination CMC/PEO gel
is a 100% synthetic gel (OXIPLEX®/SP Adhesion Barrier
Gel, manufactured by FzioMed, Inc. San Luis Obispo, CA,
USA and distributed under the trade names OXIPLEX®/SP
Adhesion Barrier Gel, DePuy International Ltd, Leeds, UK
and MEDISHIELD™ Adhesion Barrier Gel, Medtronic
International Trading SARL, Tolochenaz, Switzerland)
which received European Class III Device approval and
became available for use in Europe in 2002 as an adhe-
sion inhibitor following spinal surgery. Preclinical [13]
and initial clinical work [14] with the combination gel
showed significant reduction of epidural fibrosis.
In our safety evaluation of this approved agent, a group of
396 patients suffering from one level disc herniation and
presenting either with radicular pain resistant to conserv-
ative treatment or with radicular pain associated with
motor or sensory loss was operated upon by the same sur-
geon in the same institution (Clinique du Parc Léopold,
Brussels, Belgium) between January 1st 2003 and Decem-
ber 31st 2005. Upon completion of a conventional micro-
discectomy, in all patients the decompressed nerve root
was systematically covered with a thin layer of [CaCL2 +
NaCl + Na carboxymethylcellulose (CMC) + polyethylene
oxide (PEO)] gel to prevent excessive growth of scar tissue.
Because of previous experience with other anti-adhesion
gels, all patients were monitored during the application of
the gel looking for changes in blood pressure. They were
all reviewed 1 and 6 weeks after surgery. The wound was
then subjectively assessed for abnormal healing, redness
or subcutaneous collections. Finally, all patients that
required reoperations for recurrent disc herniation were
carefully evaluated perioperatively for scar tissue forma-
tion on the incriminated nerve roots as an assessment of
efficacy of the CMC/PEO gel in reducing fibrosis forma-
tion. The work was reviewed by the local ethics committee
and performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki with
patients giving their informed consent prior to inclusion
in the evaluation.
Results
Handling and use of the gel was simple. No patient pre-
sented with any clinically measurable adverse event dur-
ing surgery at the time of the application of the gel. The
mean length of stay after surgery was 5 days, consistent
with normal regional practice. Subjective reviews at both
week 1 and week 6 post-surgery demonstrated no local
skin reaction and no postoperative fluid collection that
required drainage. One patient required reoperation after
13 days for an infection of the wound, but we encoun-
tered no other abnormalities in wound healing. Five other
patients needed reoperations for recurrent herniation, two
after less than a week, one after one month, and two
within the first year after surgery.
In perioperative assessment of the early reoperations, as
expected, there was little or no scar tissue. However,
although anecdotal, it is worth mentioning that clinically
significant fibrosis reduction was observed in the three
patients presenting with delayed recurrences – one patient
reoperated after one month and the two patients reoper-
ated within the first year. Figure 1 provides a perioperative
view of the operative field in the patient who had recur-
rent disc herniation one year after initial surgery with
CMC/PEO gel. Note the clear limits of the L5 lumbar
nerve root (arrow) and the lack of adherent scar tissue.
This allowed facilitated dissection and separation of the
nerve root from the surrounding tissues. At the end of the
reoperation CMC/PEO gel was used again. The herniationAnnals of Surgical Innovation and Research 2008, 2:2 http://www.asir-journal.com/content/2/1/2
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did not recur and the clinical evolution of this patient was
uneventful.
Discussion
The first gels to be used for prevention of fibrosis were
semi-synthetic carbohydrate polymers such as GT 1587
(Adcon-L®, Gliatech Inc.). Initial animal models proved
favorable [15,16] and subsequent clinical research [6-8]
indicated the agent was effective in reducing fibrosis. It is
our local policy to closely monitor new agents as they are
adopted in routine surgery and with the introduction of
GT 1587 we commenced evaluation on a consecutive
series of patients in whom we used the agent. After treat-
ing 46 patients with GT 1587 we identified three patients
with painful erysipeloïd-like skin reactions. Two other
patients needed reoperations for unexplained painful sub-
cutaneous fluid collections which proved not to be infec-
tion related. The possibility of an exsudative reaction to
GT 1587 attributed to its animal gelatin a component was
put forward. A local complication rate of 10.8% was
found unacceptable in our local risk benefit assessment
and we stopped using this gel at an early stage. (Personal
presentations; Belgian Neurosurgical Society, 2004). Fur-
ther reports of serious complications associated with the
use of GT 1587 began emerging in the literature after the
gel had gone into routine clinical use, including per-oper-
ative tachycardia and hypotension [3] and increased rate
of CSF leakage [4,5]. GT 1587 was subsequently with-
drawn from use.
Our personal experiences with GT1587 highlighted the
need for close postoperative vigilance with the use of new
products even though it was approved for clinical use as
having met the essential requirements of the European
Medical Devices Directive [9]. A similar issue recently
arose with a promising new anti-adhesion gel in gyneco-
logical surgery resulting in withdrawal of the agent after
both European and USA approval of the device [17]. On
the basis of this latter experience, with the European
approval of a subsequent adhesion-reduction solution for
gynecological and general surgery, a Europe-wide safety
registry was established to allow coordinated close moni-
toring of the device as it went into routine surgical use
[18,19].
The results of our clinical safety assessment of CMC/PEO
in spinal surgery were positive. While not a randomized
controlled clinical efficacy study, this case series repre-
sented responsible safety monitoring of an approved
agent. In the case series, we experienced no complications
related to use of CMC/PEO gel and only five patients
needed reoperations for recurrent herniation, which was
lower than our previous experience (Personal presenta-
tions Société Francophone de Neurochirurgie du Rachis
2006 and European Association of Neurological Societies
2006). It should be noted that, according to communica-
tions with the manufacturer of this device (FzioMed, Inc.),
that nearly 100,000 units have been distributed world-
wide since the product was introduced in 2002 and thus
far, there have been no reports of adverse events that were
attributable to the device.
While perioperative bleeding control, avoidance of exces-
sive nerve root retraction and nucleus remnants during
surgery, as well as adequate decompression remain the
cornerstones of FBSS prevention – we believe the use of an
interposition agent is an important element of an overall
anti-adhesion strategy.
Conclusion
In close monitoring of use in a large consecutive case
series, there were no adverse events related to the use of
the CMC/PEO gel. On the basis of this safety evaluation,
we are currently using CMC/PEO on a routine basis for all
microdiscectomy procedures as part of our overall anti-
Perioperative view of the operative field for recurrent disc  herniation one year after initial surgery with CMC/PEO gel Figure 1
Perioperative view of the operative field for recurrent disc 
herniation one year after initial surgery with CMC/PEO gel. 
Note the clear limits of the L5 lumbar nerve root (arrow) 
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adhesion strategy and await the finding of prospective
control based efficacy studies with interest.
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